Literature DB >> 20804478

Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.

Marc A Dall'Era1, Janet E Cowan, Jeffrey Simko, Katsuto Shinohara, Benjamin Davies, Badrinath R Konety, Maxwell V Meng, Nannette Perez, Kirsten Greene, Peter R Carroll.   

Abstract

UNLABELLED: Study Type--Therapy (case control) Level of Evidence 3b. What's known on the subject? and What does the study add? The risks of delayed radical prostatectomy for men who progress on active surveillance are largely unknown. Two series have reported that prostatectomy after active surveillance has similar results to immediate therapy. Our data add to this growing body of evidence that appropriately selected men with prostate cancer can undergo active surveillance with delayed prostatectomy without added risk of missing an opportunity for cure as the majority of tumours remain organ confined.
OBJECTIVE: • To compare the pathological outcomes of men undergoing radical prostatectomy (RP) after a period of active surveillance (AS) with those of a similar risk group undergoing immediate surgery. PATIENTS AND METHODS: • We identified men through our institutional database who underwent RP within 6 months of diagnosis or after a period of AS. The primary outcome of the present study was Gleason upgrade to ≥7 after prostatectomy. • Pathological stage and positive surgical margin rate were assessed as secondary outcomes. Binomial logistic regression models were used to determine associations of treatment subgroups with pathological upgrade, upstage and positive margins.
RESULTS: • Thirty-three men with initially low-risk cancer features underwent RP after a median (range) of 18 (7-76) months of AS. A total of 278 men with low-risk disease features underwent immediate RP within 6 months of diagnosis. Rates of Gleason upgrading to ≥7, pathological category pT3 and positive surgical margins did not differ significantly from the immediate RP group. • On multivariate analysis of low-risk patients, adjusting for baseline pathological features, treatment group (AS followed by prostatectomy vs immediate prostatectomy) was not associated with Gleason upgrading (odds ratio, OR, 0.35; 95% CI, 0.12-1.04), non-organ-confined disease (OR, 1.67; 95% CI, 0.32-8.65) or positive surgical margins at prostatectomy (OR, 0.95; 95% CI, 0.16-5.76).
CONCLUSION: • The present analysis did not show an association between RP after a period of AS and adverse pathological features for men with low-risk disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20804478     DOI: 10.1111/j.1464-410X.2010.09589.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  17 in total

1.  Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer.

Authors:  Katsuyoshi Hashine; Hiroyuki Iio; Yoshiteru Ueno; Shohei Tsukimori; Iku Ninomiya
Journal:  Int J Clin Oncol       Date:  2013-06-22       Impact factor: 3.402

2.  [Active surveillance of low risk prostate cancer].

Authors:  K Lellig; B Beyer; M Graefen; D Zaak; C Stief
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 3.  Prostate cancer in 2010: GSU: misclassification or biological progression?

Authors:  Umberto Capitanio; Nazareno Suardi
Journal:  Nat Rev Urol       Date:  2011-02       Impact factor: 14.432

Review 4.  Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer.

Authors:  Christopher J Welty; Matthew R Cooperberg; Peter R Carroll
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

5.  Role of active surveillance in the management of localized prostate cancer.

Authors:  Allison S Glass; Matthew R Cooperberg; Maxwell V Meng; Peter R Carroll
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.

Authors:  H Ballentine Carter
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

7.  Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.

Authors:  John W Davis; John F Ward; Curtis A Pettaway; Xuemei Wang; Deborah Kuban; Steven J Frank; Andrew K Lee; Louis L Pisters; Surena F Matin; Jay B Shah; Jose A Karam; Brian F Chapin; John N Papadopoulos; Mary Achim; Karen E Hoffman; Thomas J Pugh; Seungtaek Choi; Patricia Troncoso; Christopher J Logothetis; Jeri Kim
Journal:  BJU Int       Date:  2015-07-04       Impact factor: 5.588

Review 8.  Timing of curative treatment for prostate cancer: a systematic review.

Authors:  Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel
Journal:  Eur Urol       Date:  2013-02-22       Impact factor: 20.096

9.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

10.  Prostate cancer mortality following active surveillance versus immediate radical prostatectomy.

Authors:  Jing Xia; Bruce J Trock; Matthew R Cooperberg; Roman Gulati; Steven B Zeliadt; John L Gore; Daniel W Lin; Peter R Carroll; H Ballentine Carter; Ruth Etzioni
Journal:  Clin Cancer Res       Date:  2012-09-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.